<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00349661</url>
  </required_header>
  <id_info>
    <org_study_id>OCLA</org_study_id>
    <nct_id>NCT00349661</nct_id>
  </id_info>
  <brief_title>Influence Of Omeprazole On The Anti-Platelet Action Of Clopidogrel</brief_title>
  <official_title>Influence Of Omeprazole On The Anti-Platelet Action Of Clopidogrel Associated To Aspirin: Double-Blind Randomized Trial Against Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <brief_summary>
    <textblock>
      Objectives: A prospective investigation of the effect of omeprazole, a proton pump inhibitor,&#xD;
      on the anti-platelet action of clopidogrel.&#xD;
&#xD;
      The main decision criterion will concern change in VASP protein phosphorylation under&#xD;
      treatment. Phosphorylation will be measured before and after administration of omeprazole&#xD;
      versus placebo in patients undergoing clopidogrel treatment.&#xD;
&#xD;
      Type of study: Single center, double blind, randomized parallel group study versus placebo,&#xD;
      comparing two treatment groups:&#xD;
&#xD;
        -  clopidogrel + omeprazole + standard regime (beta-blockers, atorvastatin, IEC, aspirin)&#xD;
&#xD;
        -  clopidogrel + placebo+ standard regime (beta-blockers, atorvastatin, IEC, aspirin)&#xD;
&#xD;
      Study population: 120 patients from the Cardiology Department of Brest University hospital,&#xD;
      Brest (France), receiving a standard treatment comprising a loading dose of clopidogrel&#xD;
      followed by a daily dose of 75 mg associated to 75 mg aspirin, will be randomized between 20&#xD;
      mg/day omeprazole and 20 mg/day placebo treatment groups. The efficacy of clopidogrel will be&#xD;
      assessed by inter-group comparison on the VASP test.&#xD;
&#xD;
      Study period: 7 days' treatment per patient. Total study period estimated at 6 months.&#xD;
&#xD;
      Expected findings: The results should confirm the suspected negative effect of omeprazole on&#xD;
      clopidogrel's impact on arterial thrombosis risk, secondarily allowing new recommendations to&#xD;
      be drawn up for this association.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preventing recurrence of thrombosis following angioplasty relies on dual-therapy associating&#xD;
      the anti-platelet agents aspirin and clopidogrel. This regime is kept up for between 1 and 6&#xD;
      months, depending on the type of stent deployed in the angioplasty. The biological&#xD;
      effectiveness of the clopidogrel treatment can be assessed by the VASP test, a new platelet&#xD;
      test, results on which have been shown to correlate with risk of thrombosis. A study we ran&#xD;
      recently strongly suggested that omeprazole was associated with a poor response to&#xD;
      clopidogrel. Omeprazole is an anti-ulcer agent frequently prescribed to prevent unwanted&#xD;
      side-effects of aspirin, making it frequently associated to clopidogrel in the aftermath of&#xD;
      angioplasty.&#xD;
&#xD;
      Study population: 120 patients from the Cardiology Department of Brest University hospital,&#xD;
      Brest (France), receiving a standard treatment comprising a loading dose of clopidogrel&#xD;
      followed by a daily dose of 75 mg associated to 75 mg aspirin, will be randomized between 20&#xD;
      mg/day omeprazole and 20 mg/day placebo treatment groups. The efficacy of clopidogrel will be&#xD;
      assessed by inter-group comparison on the VASP test.&#xD;
&#xD;
      Study period: 7 days' treatment per patient. Total study period estimated at 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>inter group comparison of VASP test</measure>
  </primary_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Coronary Heart Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>impact on VASP test</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient with indication of aspirin and clopidogrel treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patient&lt;18 years&#xD;
&#xD;
          -  liver disease&#xD;
&#xD;
          -  drug eluting stent&#xD;
&#xD;
          -  gastrointestinal ulcus&#xD;
&#xD;
          -  bleeding&#xD;
&#xD;
          -  pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>martine gilard, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>PI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiology</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <study_first_submitted>July 6, 2006</study_first_submitted>
  <study_first_submitted_qc>July 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2006</study_first_posted>
  <last_update_submitted>August 22, 2008</last_update_submitted>
  <last_update_submitted_qc>August 22, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2008</last_update_posted>
  <keyword>clopidogrel</keyword>
  <keyword>omeprazole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

